中心(范畴论)
计算生物学
生物
遗传学
生物信息学
医学
化学
结晶学
作者
Sofía Gouveia,Maria Eugenia Vázquez-Mosquera,Emiliano González‐Vioque,Jose Victor Álvarez,Roi Chans-Gerpe,Francisco Laranjeira,Esmeralda Martins,Ana Cristina Ferreira,Alejandro Ávila-Álvarez,María Luz Couce
出处
期刊:Genes
[Multidisciplinary Digital Publishing Institute]
日期:2021-08-19
卷期号:12 (8): 1262-1262
被引量:23
标识
DOI:10.3390/genes12081262
摘要
Next-generation sequencing (NGS) technologies have been proposed as a first-line test for the diagnosis of inborn errors of metabolism (IEM), a group of genetically heterogeneous disorders with overlapping or nonspecific phenotypes. Over a 3-year period, we prospectively analyzed 311 pediatric patients with a suspected IEM using four targeted gene panels. The rate of positive diagnosis was 61.86% for intermediary metabolism defects, 32.84% for complex molecular defects, 19% for hypoglycemic/hyperglycemic events, and 17% for mitochondrial diseases, and a conclusive molecular diagnosis was established in 2-4 weeks. Forty-one patients for whom negative results were obtained with the mitochondrial diseases panel underwent subsequent analyses using the NeuroSeq panel, which groups all genes from the individual panels together with genes associated with neurological disorders (1870 genes in total). This achieved a diagnostic rate of 32%. We next evaluated the utility of a tool, Phenomizer, for differential diagnosis, and established a correlation between phenotype and molecular findings in 39.3% of patients. Finally, we evaluated the mutational architecture of the genes analyzed by determining z-scores, loss-of-function observed/expected upper bound fraction (LOEUF), and haploinsufficiency (HI) scores. In summary, targeted gene panels for specific groups of IEMs enabled rapid and effective diagnosis, which is critical for the therapeutic management of IEM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI